Phase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022
Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular Permeability
Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats
Diabetes, 60:1590–1598, May 2011
Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism
Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
Rezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editions
Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers
The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial
ENDO 2015 Annual Meeting
